Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript

Sophie Voruz; Sabine Blum; Laurence de Leval; Jacqueline Schoumans; Françoise Solly; Olivier Spertini

doi:10.1186/s40364-021-00343-3

Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript

Biomark Res. 2021 Dec 20;9(1):92. doi: 10.1186/s40364-021-00343-3.

Authors

Sophie Voruz^{1

2}, Sabine Blum^{3

4}, Laurence de Leval⁵, Jacqueline Schoumans⁶, Françoise Solly³, Olivier Spertini^{7

8

9}

Affiliations

¹ Service and Central Laboratory of Hematology, Lausanne University Hospital (CHUV), Lausanne, Switzerland. sophie.voruz@chuv.ch.
² Service and Central Laboratory of Hematology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, CH-1011, Lausanne, Switzerland. sophie.voruz@chuv.ch.
³ Service and Central Laboratory of Hematology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
⁴ Lausanne University (UNIL), Lausanne, Switzerland.
⁵ Institute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and Lausanne University, Lausanne, Switzerland.
⁶ Oncogenomics laboratory, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
⁷ Service and Central Laboratory of Hematology, Lausanne University Hospital (CHUV), Lausanne, Switzerland. olivier.spertini@chuv.ch.
⁸ Service and Central Laboratory of Hematology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, CH-1011, Lausanne, Switzerland. olivier.spertini@chuv.ch.
⁹ Lausanne University (UNIL), Lausanne, Switzerland. olivier.spertini@chuv.ch.

Abstract

Relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) has a very poor prognosis with a median overall survival of four to nine months. Achieving a complete molecular response is most often required to obtain a sustained leukemia-free survival after allogeneic hematopoietic stem cell transplantation. Immunotherapies targeting CD19, CD20, or CD22 are very efficient in achieving this goal. However, in the absence of the expression of these immunotherapeutic targets by lymphoblasts, treatment options are extremely scarce. We report the successful treatment of a 26-year-old man who suffered R/R, CD19, CD20, and CD22 negative B-ALL targeting Bcl-2 and CD38 by combining venetoclax and daratumumab with chemotherapy.

Keywords: Adult B-cell lymphoma/leukemia; Bcl-2; CD38; Chemotherapy regimen; Daratumumab; Immunotherapies; Refractory disease; Relapsed/refractory B-cell precursor acute lymphoblastic leukemia; Targeted treatment; venetoclax.

Publication types

Letter